Why are CJC-1295 and Ipamorelin used together?

They activate two different receptor systems that both drive GH release. Combined, they produce synergistic GH release — typically 5-10x baseline compared to 2-3x for either alone.

What does a typical CJC-1295/Ipamorelin protocol look like?

Standard protocols use 100-300 mcg of each peptide subcutaneously, once daily before bed. Most follow a 5-days-on, 2-days-off pattern. Effects become noticeable within 4-8 weeks with progression over 6-12 months.

CJC-1295 and Ipamorelin Stack for Clinic Operators: The Anti-Aging Workhorse Protocol That Pays the Rent

Last updated: May 13, 2026 · Tamerlan Musayev, Founder & Technical Architect, PeptideLeads

Author note:

I'm not a doctor. I'm a data scientist and patient-acquisition architect who works exclusively with peptide therapy and regenerative medicine clinics. The CJC-1295 and Ipamorelin stack is not the most exciting peptide protocol in your portfolio. It's not the one that gets the FDA press releases (that's Tesamorelin). It's not the one that triggers the regulatory reclassification news cycle (that's BPC-157). It's not the one that produces the dramatic Phase 3 weight loss headlines (that's Retatrutide). The CJC-1295/Ipamorelin stack is the workhorse. It's the protocol that 80% of anti-aging clinics build their actual revenue around. It's the most widely prescribed growth hormone secretagogue combination in regenerative medicine. And it's the protocol that, more than any other in your stack, separates the clinics that understand patient retention from the clinics that don't. If you're a patient researching CJC-1295 or Ipamorelin, the Clinical Overview & Patient FAQ section toward the bottom is for you. Everything else is operator-level.

Why the GH secretagogue stack is the operational center of cash-pay anti-aging medicine

Reason 1: Patient lifecycle alignment. Anti-aging patients don't come into your clinic for a 90-day protocol and leave. They come in expecting an indefinite relationship. The GH secretagogue stack is built for that expectation. Patients on appropriate dosing protocols maintain therapy for 12, 18, 24 months and beyond. That's the patient relationship that compounds revenue.

Reason 2: Demographic precision. The target demographic is the easiest to acquire and retain in cash-pay medicine — adults 40-65 with disposable income, motivated by visible aging indicators (body composition, sleep quality, recovery, skin elasticity), and educated enough to understand “supporting your body's own GH production” versus “injecting synthetic hormones.”

Reason 3: Stack natural anchoring. Patients who start on CJC-1295/Ipamorelin become candidates for almost every other protocol in your portfolio over the 12-month relationship. Hormone optimization. NAD+ IV therapy. BPC-157 for joint support. Tesamorelin for residual visceral fat. The GH secretagogue stack is the gateway protocol that surfaces every other clinical conversation. Clinics that recognize this produce 2-4x the LTV of clinics that treat CJC-1295/Ipamorelin as a standalone product.

The bottom-line strategic insight: your clinic's revenue ceiling is largely determined by how well you build the GH secretagogue stack into the center of your patient acquisition and retention architecture.

The mechanism: why CJC-1295 and Ipamorelin produce synergistic GH release

The GHRH pathway: Growth hormone-releasing hormone binds to GHRH receptors on somatotroph cells in the anterior pituitary, increasing intracellular cyclic AMP and triggering GH synthesis and release. This pathway primarily increases the amplitude of GH pulses.

The ghrelin pathway: Ghrelin (and ghrelin mimetics) bind to growth hormone secretagogue receptors (GHS-R1a) on the same somatotroph cells, also stimulating GH release through a different intracellular cascade. This pathway increases both amplitude and frequency of GH pulses.

CJC-1295 is a GHRH analog. Ipamorelin is a selective ghrelin receptor agonist. When administered together, they simultaneously activate both pathways, producing GH release typically 5-10x baseline compared to 2-3x for either single agent.

Reference: Bowers et al., 1991; Walker et al., “Effects of CJC-1295 on GH and IGF-1 in healthy adults.” JCEM, 2006.

The CJC-1295 distinction: with DAC vs without DAC

CJC-1295 with DAC (Drug Affinity Complex)

Long-acting variant that binds to serum albumin. Produces sustained GH/IGF-1 elevation lasting 6+ days from a single injection. IGF-1 rises 1.5-3x baseline. Convenient dosing but produces continuous rather than pulsatile GH exposure.

CJC-1295 without DAC (Mod GRF 1-29)

Short-acting variant with ~30-minute half-life. Produces sharp, clean GH pulse that clears quickly. Preferred for stacking with Ipamorelin for coordinated pulsatile release. Mimics natural physiology, fewer side effects (water retention, joint discomfort, IGF-1 overshoot).

The clinical preference in 2026 has consolidated around CJC-1295 without DAC for the stacked protocol. For operator-level diligence: confirm specifically whether your compounding pharmacy is supplying with DAC or without DAC. The distinction matters clinically.

The dosing protocols that work in real clinical practice

Initiation phase (Week 1-2)

100 mcg CJC-1295 (no DAC) + 100 mcg Ipamorelin, once daily before bed. Lower dose introduction for response and tolerability assessment.

Standard maintenance (Week 3+)

200-300 mcg CJC-1295 (no DAC) + 200-300 mcg Ipamorelin, once daily before bed. Bedtime dosing aligns with natural GH pulse during deep sleep.

Higher-protocol (performance demographics)

250-300 mcg each, twice daily (morning + bedtime). For performance and body composition patients seeking more pronounced effects.

Cycle structure

5 days on, 2 days off per week. The washout prevents receptor desensitization. Continuous low-dose maintenance also viable with monthly IGF-1 monitoring.

Reconstitution math: Standard 5mg vial reconstituted with 2mL bacteriostatic water = 2.5mg/mL concentration. At 250mcg dose = 10 units on a U-100 insulin syringe.

The patient demographic that pays for CJC-1295/Ipamorelin

Demographic 1: Anti-aging maintenance patients. Ages 40-60, household income $100K-$300K, motivated by body composition decline, sleep quality, recovery time, skin elasticity, energy levels. Average annual stack spend: $4,800-$8,400. Stack adoption: 60-75% adopt adjacent protocols within 6 months.

Demographic 2: Performance and recovery patients. Ages 35-55, typically active or competitive athletically. Average annual stack spend: $6,000-$10,800 (higher dosing protocols). Stack adoption: 75-90% adopt GH-adjacent protocols.

Demographic 3: Executive longevity patients. Ages 45-65, household income $250K+, comprehensive longevity protocols. Average annual stack spend: $5,400-$9,600. Stack adoption: 85-95% adopt comprehensive longevity stacks.

Demographic 4: Aesthetic-focused patients. Ages 40-65, predominantly women, motivated by skin quality and visible anti-aging. Average annual stack spend: $3,600-$6,000. Stack adoption: 40-55% adopt aesthetic protocols.

The patient lifetime value math

Patient Profile	Avg Annual Stack Spend	Stack Adoption	Total 24-Month LTV
Anti-aging maintenance	$4,800-$8,400	60-75% adopt adjacent	$14,000-$26,000
Performance and recovery	$6,000-$10,800	75-90% adopt GH-adjacent	$20,000-$38,000
Executive longevity	$5,400-$9,600	85-95% comprehensive	$30,000-$55,000
Aesthetic-focused	$3,600-$6,000	40-55% aesthetic protocols	$9,500-$18,000

Source: PeptideLeads Internal Network Data, Q1-Q2 2026.

The pricing decision that determines clinic margin on the stack

Per-protocol pricing: $400-$800/month for medication stack alone plus consultation and follow-up fees. Standard model for most cash-pay clinics.

Bundled membership pricing: $600-$1,200/month including medications, consultations, follow-up, and basic lab work. Higher satisfaction, predictable revenue.

Concierge longevity programs: $1,500-$3,500/month including GH secretagogue stack, integrated protocols, comprehensive labs, dedicated clinical coordinator. Highest LTV, smallest market, significant infrastructure required.

The structural pricing reality: CJC-1295/Ipamorelin wholesale costs at most legitimate compounding pharmacies run approximately $80-$150/month for the combined stack at standard dosing. The patient-facing price builds in clinical overhead, staff time, facility costs, and margin. Clinics pricing below $400/month are running tight margins that don't accommodate proper protocol monitoring.

The compliance architecture for CJC-1295/Ipamorelin marketing in 2026

Neither CJC-1295 nor Ipamorelin is FDA-approved. Both are used exclusively off-label, sourced through 503A compounding pharmacies.

The marketing language that works:

“Growth hormone secretagogue therapy”
“Supporting your body's natural GH production”
“Protocol designed for adults experiencing age-related GH decline”
“Physician-supervised peptide therapy”

The marketing language that creates exposure:

“Increases human growth hormone” (reads as direct hormone claim)
“Anti-aging treatment” (treatment claim for unapproved indication)
“Weight loss medication” (off-label implication)
“HGH alternative” or “natural HGH”
Specific outcome promises (body fat percentages, sleep quality scores)

LegitScript certification

LegitScript Healthcare Certification requires physician oversight, patient screening (baseline IGF-1, glucose tolerance, contraindication screening), compliant marketing language, and sourcing transparency from documented 503A pharmacy. Cost remains $975 application + $2,150 annual. Essentially required for Meta and Google advertising.

The sourcing decision: compounding pharmacy quality determines patient outcomes

Tier 1 compounding pharmacy

USP <797> sterile compounding compliance. USP <85> endotoxin testing. Mass spectrometry COA. PCAB certification. Specific CJC-1295 without DAC when requested.

Tier 2 compounding pharmacy concerns

Sterility testing variable. COA not provided on request. Substitution of CJC-1295 with DAC when no-DAC was prescribed. Pricing significantly below market.

Tier 3 (not appropriate for clinic prescribing)

Research-grade vendors selling directly to consumers. Pharmacies outside licensure scope. Any source without documented chain of custody.

Ipamorelin quality verification

Ipamorelin's pentapeptide structure (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) has been documented in some compounding sources as substituted with GHRP-2, GHRP-6, or hexarelin. These produce different clinical profiles, particularly elevated cortisol and prolactin — exactly the side effects Ipamorelin's selectivity was designed to avoid.

The diligence question:

“Can you confirm via mass spectrometry that the Ipamorelin you're supplying matches the pentapeptide molecular weight of 711.85 Da?” Substituted GHRP-2 or GHRP-6 will show different molecular weights and clinical profiles.

Patient acquisition strategy for CJC-1295/Ipamorelin clinics

Audience targeting

Anti-aging maintenance: Anti-aging, longevity research, hormone optimization, executive health interests. 40-65, balanced gender, household income $100K+.

Performance and recovery: Athletic performance, recovery optimization, body composition. 35-55, 65% male, household income $125K+.

Executive longevity: Longevity protocols, biohacking, comprehensive wellness. Whoop/Oura users, longevity podcast listeners. 45-65, executive/founder, household income $250K+.

Patient acquisition benchmarks

Cost per qualified GH secretagogue lead (Meta, LegitScript certified): $14-$38
Lead to booked consultation rate: 42-58%
Consultation to enrolled patient: 30-45%
Combined CAC for retained patient: $180-$420

Against the anti-aging maintenance LTV of $14,000-$26,000 and the executive longevity LTV of $30,000-$55,000, the LTV-to-CAC ratio sits between 33:1 and 305:1. Among the most favorable ratios in cash-pay medicine.

How CJC-1295/Ipamorelin stacks with the broader peptide protocol portfolio

CJC-1295/Ipamorelin + BPC-157. GH/IGF-1 elevation increases tissue turnover; BPC-157 supports soft tissue and joint health during increased anabolic activity. Strong across all four demographics.

CJC-1295/Ipamorelin + Tesamorelin. For patients with significant visceral adiposity alongside GH optimization goals. Most common in performance and executive longevity demographics.

CJC-1295/Ipamorelin + NAD+ IV therapy. Cellular energy and mitochondrial function alongside GH optimization. Compound effects on energy, recovery, and longevity markers. Particularly strong in executive longevity demographic.

CJC-1295/Ipamorelin + Hormone optimization. For patients with documented endocrine deficiencies. Most clinically sophisticated stack and highest LTV combination across demographics.

CJC-1295/Ipamorelin + GHK-Cu. Tissue regeneration and skin quality effects complement systemic GH effects. Most common in aesthetic-focused demographic.

The strategic insight: the GH secretagogue stack is rarely the patient's only protocol after 6 months. Clinics that build consultation flows to surface adjacent opportunities at the 90-day follow-up capture the higher LTV figures.

How peptide therapy clinics work with PeptideLeads on GH secretagogue acquisition

PeptideLeads operates patient acquisition campaigns specifically calibrated for the four CJC-1295/Ipamorelin demographic profiles. The $50/qualified lead pricing model applies. Clinics receive pre-qualified patient inquiries with demographic signals indicating fit with anti-aging maintenance, performance/recovery, executive longevity, or aesthetic-focused profiles.

For clinic operators evaluating the GH secretagogue stack as a protocol category, the Get Matched intake form is the starting point. We respond within 24 hours with a market-specific assessment of patient demand, recommended demographic targeting, and pricing structure recommendations.

Related operator resources

Clinical Overview & Patient FAQ

This section is written for patients researching CJC-1295 and Ipamorelin, not for clinic operators. The information below is for educational purposes and does not constitute medical advice. Always consult a licensed medical provider before considering any peptide therapy protocol.

What are CJC-1295 and Ipamorelin?

CJC-1295 is a synthetic growth hormone-releasing hormone (GHRH) analog. Ipamorelin is a selective ghrelin receptor agonist (also called a growth hormone-releasing peptide, or GHRP). Both compounds stimulate the body's pituitary gland to produce and release its own endogenous growth hormone (GH) through different but complementary signaling pathways.

Why are they used together?

CJC-1295 and Ipamorelin activate two different receptor systems that both drive GH release. When combined, they produce a synergistic effect — typically 5-10x baseline GH release compared to 2-3x for either peptide alone. This is the mechanistic basis for the stack being the most widely prescribed GH secretagogue combination in regenerative medicine.

Are CJC-1295 and Ipamorelin FDA-approved?

No. Neither compound is FDA-approved for any medical indication. Both are used exclusively off-label in cash-pay clinical practice, sourced through state-licensed 503A compounding pharmacies based on individual patient prescriptions.

What's the difference between CJC-1295 with DAC and without DAC?

CJC-1295 with DAC (Drug Affinity Complex) is a long-acting variant that produces sustained GH and IGF-1 elevation lasting several days from a single injection. CJC-1295 without DAC (also called Mod GRF 1-29) has a short half-life of approximately 30 minutes and produces pulsatile GH release. Most modern clinical protocols use CJC-1295 without DAC because it more closely mimics the body's natural GH release pattern and produces fewer side effects.

What does a typical protocol look like?

Standard protocols use 100-300 mcg of each peptide subcutaneously, typically once daily before bed. The bedtime timing aligns with the body's natural GH pulse during deep sleep. Most protocols follow a 5-days-on, 2-days-off pattern to prevent receptor desensitization. Effects on body composition, sleep quality, and recovery typically become noticeable within 4-8 weeks, with continued progression over 6-12 months.

What are the benefits?

Reported benefits include improved body composition (modest fat reduction, lean mass support), enhanced recovery from exercise, improved sleep quality, increased energy, and various effects associated with optimized GH levels in aging adults. A 2024 prospective study found 10-15% reductions in visceral fat and modest lean mass gains over 12 months.

What are the side effects?

Common reported side effects include injection site reactions, mild water retention, occasional tingling sensations during the first few weeks, and mild joint discomfort in some patients. Ipamorelin's selectivity means it does not significantly elevate cortisol or prolactin at therapeutic doses, distinguishing it from less selective GHRPs like GHRP-6.

Who should not use CJC-1295/Ipamorelin?

The stack is contraindicated in patients with active malignancy, uncontrolled diabetes, pituitary disorders, or known hypersensitivity to either compound. Pregnancy is a contraindication. Use should be carefully evaluated in patients with prior or current cancer concerns, given GH/IGF-1's potential role in cellular proliferation.

How much does CJC-1295/Ipamorelin therapy cost?

Pricing varies by clinic positioning. Per-protocol pricing runs $400-$800/month for medication. Bundled memberships run $600-$1,200 monthly. Concierge longevity programs run $1,500-$3,500 monthly. Initial consultation and baseline lab work add $400-$1,000 to startup costs. Insurance does not cover peptide therapy for anti-aging indications.

Can I use CJC-1295/Ipamorelin with other peptides?

Most clinical protocols include the GH secretagogue stack alongside other peptides (BPC-157, Tesamorelin) and hormone optimization. Combination protocols should be designed by a qualified clinician. The stack should not be combined with exogenous human growth hormone (HGH), as this defeats the purpose and increases IGF-1 overshoot risk.

How do I find a compliant CJC-1295/Ipamorelin clinic?

Look for clinics with documented physician oversight, LegitScript Healthcare Certification, transparency about compounding pharmacy partnerships, willingness to provide Certificate of Analysis documentation, baseline and ongoing IGF-1 monitoring, clear distinction between CJC-1295 with DAC and without DAC formulations, and marketing language that doesn't make unapproved treatment claims. Be cautious of clinics with significantly below-market pricing. Get matched with a clinic in your area through our intake form, which connects patient inquiries with vetted peptide therapy and regenerative medicine practices.

Tamerlan Musayev is the Founder and Technical Architect of PeptideLeads, a patient acquisition platform for peptide therapy and regenerative medicine clinics. He is not a licensed medical provider. All clinical guidance in this document is sourced from peer-reviewed research, FDA regulatory documents, and published clinical and pharmacovigilance data. It is intended for clinic operators evaluating protocol additions and patient acquisition strategy, not for direct patient application. Operational guidance reflects publicly available best practices in regenerative medicine sourcing and marketing compliance. Clinic operators should consult licensed pharmacists, attorneys, and medical directors for specific compliance decisions in their state of operation.

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Peptide therapies should only be administered by licensed healthcare providers. Always consult with a qualified healthcare professional before starting any new treatment. PeptideLeads is a marketing agency and does not provide medical services.